Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

639 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple-Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1-Regulated Cholesterol Metabolism.
Yang Y, Liao J, Pan Z, Meng J, Zhang L, Shi W, Wang X, Zhang X, Zhou Z, Luo J, Chen X, Yang Z, Mei X, Ma J, Zhang Z, Jiang YZ, Shao ZM, Chen FX, Yu X, Guo X. Yang Y, et al. Among authors: shao zm. Adv Sci (Weinh). 2024 Dec 10:e2413103. doi: 10.1002/advs.202413103. Online ahead of print. Adv Sci (Weinh). 2024. PMID: 39656925
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, Ren Y, Wang S, Fu P, Yang H, Liu Y, Sun J, Nie J, Lei R, Yao Y, Zhang A, Wang S, Ma X, Ouyang Z, Yang H, Wu SY, Cao SW, Wang K, Jiang A, Ouyang Q, Pang D, Wei L, Zha X, Shen Y, Qu X, Wu F, Zhu X, Wang Z, Fan L, Shao ZM. Chen L, et al. Among authors: shao zm. JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.23560. Online ahead of print. JAMA. 2024. PMID: 39671272
Precision medicine for breast cancer: advances and challenges.
Liu XY, Yu TJ, Shao ZM. Liu XY, et al. Among authors: shao zm. Transl Breast Cancer Res. 2024 Oct 31;5:35. doi: 10.21037/tbcr-24-35. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534585 Free PMC article. No abstract available.
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, Tang LC, Mo M, Hou YF, Di GH, Liu GY, Yu KD, Wu J, Yan X, Zeng XH, Fu DY, Song CG, Zhuang ZG, Wu KJ, Wang J, Wang ZH, Shao ZM. He M, et al. Among authors: shao zm. BMJ. 2024 Oct 23;387:e079603. doi: 10.1136/bmj-2024-079603. BMJ. 2024. PMID: 39442958 Free PMC article. Clinical Trial.
639 results